17 September 2024
N4 Pharma
plc
("N4 Pharma" or the
"Company")
SRI Research
Update
N4 Pharma Plc (AIM: N4P), the
specialist pharmaceutical company developing Nuvec®, a novel
delivery system for cancer treatments, gene therapy and vaccines,
is pleased to provide a further update on its work with SRI
International ("SRI").
Further to the Company's
announcement on 20 August 2024, the Company has now successfully
demonstrated that the selected cargo, when combined with
Nuvec® and SRI's Fox Three Molecular
Guidance System ("MGS"), is performing as
expected and has therefore completed the first stage of its
collaboration project with SRI. More information will be
released soon.
Find more information and an
additional video by Nigel Theobald, CEO and submit any questions
via the N4 Pharma investor hub: https://investors.n4pharma.com/link/MrDmnP.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"We have now shown that not only is
Nuvec® capable of modification with
a ligand to target specific cells, but also that the combined new
Nuvec® nanoparticle retains its ability to knockdown the target
gene.
"We will add this information to our combined marketing pitch
deck and both SRI and N4 Pharma will present this data and its
implications to major pharma and biotech players that need a
targeting delivery system for their nucleic acid
programs."
For
more information please contact:
|
N4
Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive
Director
Engage with us directly at N4 Pharma
Investor Hub
To hear more, visit
|
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
|
|
SP
Angel Corporate Finance
LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe
(Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob
Rees (Corporate Broking)
|
Tel: +44(0)20 3470 0470
|
|
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
|
Tel: +44(0)20 3657 0050
|
|
|
|
About N4 Pharma
N4 Pharma is a specialist
pharmaceutical company developing a novel delivery system for
oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec® and Liptide, a unique
peptide/lipid delivery system via its subsidiary
Nanogenics.
N4 Pharma's business model is to
partner with companies developing products in these fields to use
Nuvec® or Liptide® as the delivery vehicle for these products. As
these products progress through pre‐clinical and clinical programs,
N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the
market.
For further information on the Company
visit www.n4pharma.com or sign up at investors.n4pharma.com.
